| Compounds | Topics | Title | Date |
|---|---|---|---|
| cannabis | safety in humans via study (n=16430) | Total and differential white blood cell count in cannabis users: results from the cross-sectional National Health and Nutrition Examination Survey, 2005-2016 | Jul 2019 |
| Negative A modest association between heavy cannabis use and WBC count was detected. Additional research is needed to understand the immune related effects of different modes of cannabis use and to elucidate the role of proinflammatory chemicals generated from smoking cannabis. | |||
| CBD | safety in mice via experiment | Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice | May 2019 |
| Our results demonstrate that prolonged CBD treatment has no negative effect on the behavior of adult C57Bl/6J mice. | |||
| Rimonabant | safety via review | Rimonabant: From RIO to Ban | Jul 2011 |
| The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects--notably severe mood disorders | |||
| CBD | safety via review | An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies | Jun 2017 |
| Neutral This review also illustrates that some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones. Additionally, more clinical trials with a greater number of participants and longer chronic CBD administration are still lacking. | |||
| CBD | metabolism,safety via review | Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy | Mar 2016 |
| The present overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD in humans, reviews studies on the biological activity of CBD metabolites either in vitro or in vivo, and discusses relevant drug-drug interactions. To facilitate further research in the area, the reported syntheses of CBD metabolites are also catalogued. | |||
| JWH-018 | metabolism,safety in humans via experiment (n=17) | Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders | Aug 2019 |
|
Ingestion Method: 2-6mg inhaled Serum concentrations of JWH-018 were significantly higher in the responders. Overall, JWH-018 increased heart rate within the first hour and significantly impaired critical tracking and memory performance. Responders to JWH-018 performed more poorly in tests measuring reaction time and showed increased levels of confusion, amnesia, dissociation, derealization, and depersonalization and increased drug liking after JWH-018. | |||
| Rimonabant | safety via review | Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. | Nov 2007 |
| Negative Our findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials. Taken together with the recent US Food and Drug Administration finding of increased risk of suicide during treatment with rimonabant, we recommend increased alertness by physicians to these potentially severe psychiatric adverse reactions. | |||
| Limonene | safety in humans | D-Limonene: safety and clinical applications. | Sept 2007 |
| Subsequent studies have determined how these tumors occur and established that d-limonene does not pose a mutagenic, carcinogenic, or nephrotoxic risk to humans. In humans, d-limonene has demonstrated low toxicity after single and repeated dosing for up to one year. | |||
| Sativex | safety in humans via placebo trial (n=17) | Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. | Jan 2009 |
| Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-na?ve patients with MS. | |||
| Rimonabant | safety via review | An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. | Feb 2011 |
| Negative Rimonabant is effective in reducing weight in the obese but may lead to intolerable adverse effects most notably psychiatric effects, which make it unsuitable for routine use. However, the drug provides useful proof of principle for this approach to weight loss. | |||
| cannabis | safety in humans via trial (n=415) | Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). | Dec 2015 |
|
Ingestion Method: 12.5% THC cannabis Positive This study evaluated the safety of cannabis use by patients with chronic pain over 1 year. The study found that there was a higher rate of adverse events among cannabis users compared with controls but not for serious adverse events at an average dose of 2.5 g herbal cannabis per day. | |||
| PTL101 | metabolism,safety in humans | Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. | Aug 2019 |
| PTL101 is a pharmaceutical-grade, user-friendly oral formulation that demonstrated safe and efficient delivery of CBD and therefore could be an attractive candidate for therapeutic indications. | |||
| CBD | safety in mice via experiment | Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. | Apr 2019 |
|
Ingestion Method: 0, 246, 738, or 2460 mg/kg Negative In conclusion, CBD exhibited clear signs of hepatotoxicity, possibly of a cholestatic nature. The involvement of numerous pathways associated with lipid and xenobiotic metabolism raises serious concerns about potential drug interactions as well as the safety of CBD. | |||
| SEDDS-CBD | safety in humans via placebo trial (n=16) | A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb(R) Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects. | Aug 2019 |
| Overall, SEDDS-CBD showed a significant improvement for all determined pharmacokinetic parameters: increased CBD plasma values (Cmax), favorably enhanced bioavailability (AUC) and fast absorption (Tmax). No safety concerns were noted following either administration. | |||